Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, milestone payments, and complex royalty schedules make Cytokinetics filings notoriously dense. Whether you’re dissecting how a cardiac myosin activator advances through Phase III or estimating the company’s cash runway, combing through hundreds of pages can stall decisive action.
Stock Titan turns that obstacle into clarity. Our AI instantly delivers Cytokinetics SEC filings explained simply, mapping each section of the Cytokinetics annual report 10-K simplified to the questions investors actually ask. Need the latest Cytokinetics quarterly earnings report 10-Q filing? We surface R&D spend and partnership revenue in seconds. Looking for Cytokinetics insider trading Form 4 transactions or Cytokinetics Form 4 insider transactions real-time? Alerts arrive the moment EDGAR posts. You can even see trial-related surprises through our summaries of Cytokinetics 8-K material events explained. Key use cases include:
- Tracking Cytokinetics executive stock transactions Form 4 before clinical read-outs
- Comparing pipeline costs across quarters with our Cytokinetics earnings report filing analysis
- Reviewing Cytokinetics proxy statement executive compensation to align leadership incentives with drug-approval timelines
- Understanding Cytokinetics SEC documents with AI-generated plain-English notes
Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A and more—is captured in real time, then distilled by our expert models. Spend less time scrolling and more time deciding when trial milestones or insider moves signal opportunity.
Cytokinetics (CYTK) disclosed a Form 4 for its EVP of Research & Development reporting insider transactions on 10/21/2025. The officer exercised 2,105 non-derivative shares via an option at $10.60 per share (code M) and sold 2,105 shares at $58.22 (code S) on the same date. Following these transactions, the reporting person directly holds 140,610 shares of common stock. A non-qualified stock option with an exercise price of $10.60, initially exercisable on 03/28/2017 and expiring on 02/28/2027, shows 1,000 derivative securities beneficially owned after the reported activity.
Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4. A company director acquired 99 shares of common stock on 10/15/2025 at a price of $62.8 per share. The filing notes the transaction code A (1), with the footnote stating, “Director equity in lieu of cash retainer program,” indicating this was a stock grant in place of cash fees.
Following the transaction, the director now beneficially owns 32,444 shares, held directly. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported an insider transaction. President & CEO sold 5,000 shares of common stock on 10/16/2025 at $60.03 per share. Following the sale, the reporting person beneficially owns 363,108 shares directly.
Additional indirect holdings are disclosed as 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics (CYTK) director reported acquiring common stock. On 10/15/2025, the director acquired 99 shares at $62.8 per share under the director equity in lieu of cash retainer program. After this transaction, the director beneficially owns 30,873 shares, held directly.
Cytokinetics (CYTK) director Dr. Kaye reported an equity grant on 10/15/2025. The filing shows acquisition of 199 shares of common stock (Transaction Code A) at a reported price of $62.8, described as “director equity in lieu of cash retainer.” Following the transaction, Dr. Kaye beneficially owns 9,977 shares, held directly. This reflects routine director compensation paid in stock rather than cash.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 338 shares of common stock at $62.8 per share, noted as part of a director equity in lieu of cash retainer program.
Following the transaction, the director beneficially owned 74,578 shares direct and 83 shares indirect through a spouse.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 199 shares of common stock at $62.8 per share. Following the transaction, the director beneficially owns 20,692 shares, held directly.
The filing notes this was director equity in lieu of a cash retainer, indicating compensation received in stock rather than cash.
Insider exercise and sale by Cytokinetics EVP R&D. On
CYTOKINETICS, Inc. director Dr. Edward M. Kaye reported a sale of 6,757 shares of common stock on
Insider sale notice for CytoKinetics (CYTK). An individual proposes to sell 6,757 common shares with an aggregate market value of
The filing also discloses recent automated sales under a 10b5-1 plan: 6,695 shares sold on
FAQ
What is the current stock price of Cytokinetics (CYTK)?
What is the market cap of Cytokinetics (CYTK)?
